Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $1,660,584.33 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the transaction, the director now owns 152,396 shares in the company, valued at $16,691,933.88. The trade was a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Blueprint Medicines Price Performance

NASDAQ:BPMC traded up $4.55 during trading hours on Thursday, reaching $115.63. The company had a trading volume of 1,479,676 shares, compared to its average volume of 990,877. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock has a 50-day moving average of $95.28 and a two-hundred day moving average of $95.48. Blueprint Medicines Co. has a one year low of $72.24 and a one year high of $121.90. The firm has a market capitalization of $7.35 billion, a PE ratio of -54.80 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same quarter in the prior year, the firm earned ($2.20) EPS. The firm’s quarterly revenue was up 126.5% compared to the same quarter last year. Analysts forecast that Blueprint Medicines Co. will post -3.67 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BPMC. Wells Fargo & Company lowered their price target on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. UBS Group began coverage on Blueprint Medicines in a report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Wednesday, January 15th. Stephens restated an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.72.

Hedge Funds Weigh In On Blueprint Medicines

Institutional investors have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of Blueprint Medicines during the third quarter valued at approximately $32,000. R Squared Ltd bought a new position in Blueprint Medicines in the 4th quarter valued at $51,000. Covestor Ltd increased its stake in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 403 shares during the period. Quantbot Technologies LP bought a new stake in shares of Blueprint Medicines during the third quarter worth $108,000. Finally, Values First Advisors Inc. acquired a new position in shares of Blueprint Medicines during the third quarter valued at $122,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.